MedPath

Cerebral Embolism (CE) in Catheter Ablation of Atrial Fibrillation (AF)

Not Applicable
Completed
Conditions
Atrial Fibrillation
Interventions
Procedure: PVI with Cooled-RF
Procedure: PVI with PVAC gold
Registration Number
NCT01361295
Lead Sponsor
Serge A. Trines
Brief Summary

Radiofrequency catheter ablation of atrial fibrillation (AF) induces a procoagulant state, which leads to an acute risk for symptomatic cerebral embolism (CE) of approximately 1%. The induction of a procoagulant state has been studied in pulmonary vein isolation (PVI) with a non-cooled tip catheter. The induction of a procoagulant state using a cooled-tip catheter has not been studied yet. Due to the avoidance of high endocardial temperatures, it can be expected that these procedures induce a lower level of procoagulation.

Recent studies showed an 11% incidence of CE on diffusion weighted (DW) MRI in patients undergoing cooled-tip catheter ablation of AF. In this study there will be used to different catheters, the cooled-tip catheter and the PVAC Gold catheter. Since the PVAC Gold catheter is equipped with non-cooled electrodes, the risk of endothelial scarring, local thrombosis and CE may be increased.

The goal of this study is to determine the effect of two different ablation catheters on the induction of a procoagulant state and the incidence of CE on DW-MRI in patients with AF undergoing PVI.

Our hypothesis is that patients with AF undergoing PVI using the PVAC gold catheter will show a higher rise in procoagulation and a higher incidence of CE on DW-MRI than patients with AF undergoing PVI with the cooled-tip catheter.

Detailed Description

A total of 70 patients scheduled for a first ablation of paroxysmal AF will be included. Patients will be 1:1 randomized to PVI using the PVAC gold catheter or the cooled-tip catheter. A control group of 20 patients with AF but without undergoing ablation is included for neuropsychological testing.

Before the procedure, the procoagulant state will be assessed by measuring several markers of endothelial damage, activated coagulation, fibrinolysis and by measurement of fibrinogen and thrombin generation. Measurements will be repeated during and after the procedure.

Documentation of the formation of CE will be established by performing a DW-MRI before and after the ablation. The proportion of symptomatic CE will be quantified by neuropsychological tests and questionnaires.

Finally, transcranial doppler will be performed during the entire procedure to quantify the number and pattern of cerebral microembolic signals (MES).

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
70
Inclusion Criteria
  • suffering from drug-refractory paroxysmal atrial fibrillation
  • scheduled for first ablation procedure
Exclusion Criteria
  • contra-indications for DW-MRI
  • previous AF-ablation
  • minors
  • any patient unable to undergo neuropsychological testing due to mental retardation

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
PVI with PVAC goldPVI with Cooled-RFPatient for pulmonal vein isolation using the PVAC Gold Catheter. Intervention.
PVI with Cooled-RFPVI with PVAC goldPatient for pulmonal vein isolation using the Cooled-RF catheter.
Primary Outcome Measures
NameTimeMethod
Cerebral embolismBetween 24 hours before the ablation and 24 hours after the ablation

Cerebral embolism will be documented with diffusion weighted MRI of the brain before and after ablation.

Secondary Outcome Measures
NameTimeMethod
Neuropsychological functioningBetween a week before the ablation until 3 months after the ablation

A decrease in neuropsychological functioning will be assessed with a questionnaire before and after the procedure

Rise in procoagulationBetween 24 hours before the ablation and 24 hours after the ablation

The procoagulant state will be assessed before, during and after the procedure by measurement of markers of endothelial damage, markers of activated coagulation, markers of fibrinolysis and by measurement of APTT, PT-INR, fibrinogen and thrombin generation.

Trial Locations

Locations (1)

Leiden University Medical Center

🇳🇱

Leiden, Zuid-Holland, Netherlands

© Copyright 2025. All Rights Reserved by MedPath